Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Postbariatric Hypoglycemia ...

An insulin that switches itself on and off in response to blood glucose levels has proven successful in lowering the risk of ...

NNC2215, a glucose-sensitive insulin, offers improved glycemic control by dynamically adjusting to blood sugar levels, ...

The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism ...

Nanosized particles that release glucagon, the hormone responsible for raising blood glucose levels, on-demand could mean ...

Groundbreaking research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) ...

The main concern when drinking alcohol with diabetes is that it can cause your blood sugar to drop very low — below 70 milligrams/deciliter (mg/dL) — known as hypoglycemia. Some alcoholic ...

No. 48 / 2024Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinismU.S. Food and ...

Zealand Pharma said it has received a complete response letter from the Food and Drug Administration related to its new drug application for dasiglucagon for the prevention and treatment of ...

According to Professor Partha Kar, National Specialty Advisor, Diabetes, NHS England and co-lead of Diabetes GIRFT, NHS ...

Zealand Pharma A/S (ZEAL) said that the U.S. Food and Drug Administration has issued a Complete Response Letter or CRL for Part 1 of ...